Germanys Curevac offers common shares
mRNA vaccine pioneer CureVac N.V. has announced that it will sell US$200m of its common shares in an underwritten public offering.
Chong Kun Dang Pharm licences Synaffix ADC platform
South Korean Chong Kun Dang Pharm has licenced access to Amsterdam-based Synaffix BVs propietary ADC platform.
New EU stakeholder platform to speed up clinical trials
A new platform is set to facilitate the exchange of information on the optimisation of the electronic reporting system CTIS.
Ultra-processed foods increase risk for cancer
British researchers have linked higher consumption of ultra-processed foods to an increased risk of developing and dying from cancer.
Evotec and Janssen team up in immunooncology
Evotec SE and Janssen Biotech Inc have agreed to co-develop targeted immuno-oncological therapies.
Evidence of deliberate climate damage
A new study adds weight to ongoing legal and political investigations against ExxonMobil for deliberate climate malfeasance.
New polymer can stop biofilm formation
British researchers have created a new polymer material that may help to prevent urinary tract infections caused by catheters
Rewind Therapeutics extends Series A financing
With Sunstone Life Siences A/S as a new investor, Belgian remyelination specialist Rewind Therapeutics has increased its 2018 Series A funding.
Henkel buys FDCA from Avantium NV
Bioplastics specialist Avantium N.V. has inked a 5-year agreement to supply Henkel with plant sugar based furandicarboxylic acid , a building block of PEF bioplastics.
Vésale Bioscience wins R&D grant
Phage therapy specialist Vésale Bioscience gas bageds 1.8m from European Innovation Council (EIC) to fight antibiotic resistance (AMR).